Alkermes announces Anne C. Whitaker's appointment to board via press release
The company confirmed the September 14 board appointment in a September 16 statement that included executive comments and details on Whitaker's background.
Alkermes plc issued a press release on September 16, 2026 announcing the appointment of Anne C. Whitaker to its board of directors. The board had increased its size from ten to eleven directors on September 14, 2026, and appointed Whitaker to the new seat immediately, with her term set to run until the company's 2027 annual general meeting of shareholders.1 As of the filing date, Whitaker had not been assigned to any board committee.1
In the release, CEO Blair Jackson said Whitaker was joining the board at a defining time for Alkermes as the company builds on its commercial performance and pipeline in neuroscience1. Board Chairman Richard Pops said Whitaker's experience as an executive and CEO across organizations of varying sizes, along with her board service, gives her a distinct perspective on decisions relevant to the industry1.
Whitaker's biopharma background includes serving as CEO of Aerami Therapeutics, a clinical-stage biopharmaceutical company at the time, and previously as CEO of Novoclem Therapeutics and Synta Pharmaceuticals1. Earlier in her career she held senior commercial and executive roles at Bausch Health Companies, Sanofi, and GlaxoSmithKline.1 She currently serves on the boards of Basilea Pharmaceutica and ICON plc, along with several private companies including QurAlis, Bespak, Beaconcure Technologies and Trinity Partners1, and previously served on the boards of Nykode Therapeutics, OraSure Technologies, Ergomed plc and Faron Pharmaceuticals1.
On compensation, Whitaker will receive an initial new director equity award with a target value of $600,000, split evenly between stock options and restricted stock units, vesting in three equal annual installments starting on the first anniversary of the grant date1. The grant is expected in October 2026, aligned with the company's monthly new-hire equity schedule.1 Alkermes and its subsidiary each entered into standard indemnification agreements with Whitaker using forms previously filed with the SEC in 2020.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.